HPV Genotyping and Site of Viral Integration in Cervical Cancers in Indian Women

Poulami Das1, Asha Thomas1, Umesh Mahantshetty2, Shyam K. Shrivastava2, Kedar Deodhar3, Rita Mulherkar1*

1 Mulherkar Lab, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India, 2 Department of Radiation Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India, 3 Department of Pathology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India

Abstract
Persistent HPV infection plays a major role in cervical cancer. This study was undertaken to identify HPV types in a cohort of Indian women with locally advanced cervical cancer as well as to determine the physical state and/or site of viral integration in the host genome. Pretreatment biopsies (n = 270) from patients were screened for HPV infection by a high throughput HPV genotyping assay based on luminex xMAP technology as well as MY09/11 PCR and SPF1/2 PCR. Overall HPV positivity was observed to be 95%, with HPV16 being most common (63%) followed by infection with HPV18. Integration status of the virus was identified using Amplification of Papillomavirus Oncogene Transcripts (APOT) assay in a subset of samples positive for HPV16 and/or HPV18 (n = 86) and with an adequate follow-up. The data was correlated with clinical outcome of the patients. Integration of the viral genome was observed in 79% of the cases and a preference for integration into the chromosomal loci 1p, 3q, 6q, 11q, 13q and 20q was seen. Clinical data revealed that the physical state of the virus (integrated or episomal) could be an important prognostic marker for cervical cancer.

Citation: Das P, Thomas A, Mahantshetty U, Shrivastava SK, Deodhar K, et al. (2012) HPV Genotyping and Site of Viral Integration in Cervical Cancers in Indian Women. PLoS ONE 7(7): e41012. doi:10.1371/journal.pone.0041012

Editor: Torbjörn Ramqvist, Karolinska Institutet, Sweden

Received February 17, 2012; Accepted June 15, 2012; Published July 16, 2012

Copyright: © 2012 Das et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors wish to express their gratitude for the financial support from Women’s Cancer Initiative IRG (C223)

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: rmulherkar@actrec.gov.in

Introduction
Cervical cancer is the third most common cancer among women worldwide and the most common cancer found in Indian women. HPV infection has been shown to play a critical, though not sufficient, role in the etiology of cervical cancers. Till date more than 200 HPV types have been reported, of which HPV16 is most common, followed generally by HPV18, HPV45, HPV31 and HPV33 [1,2]. Most of the high risk HPV (HR-HPV) infections (90%) regress spontaneously and only in about 10% cases the infection persists and progresses to high-grade cervical intraepithelial neoplasia. This generally occurs through integration of the HPV genome into the host chromosome with associated loss or disruption of E2 [3]. According to available reports, viral E2 gene has the ability to repress viral E6 and E7 oncogenes in cells harbouring integrated HPV DNA [4]. Therefore integration of the virus with loss of transcriptional control by E2 results in overexpression of E6 and E7 leading to immortalization and transformation of cells [5]. In most of the cases integration of HR-HPV genome gives rise to fusion transcripts comprising of viral oncogenes E6, E7 and adjacent cellular sequences [6,7,9,9]. In vitro studies have demonstrated that the viral-cellular fusion transcripts are more stable and impart the cells with a selective growth advantage as compared to the episomal counterparts [10,11].

Studies report that the integration event is random involving almost all the chromosomes, and accordingly several virus-host integration sites have been mapped till date [12]. However, there are certain hotspots e.g., fragile sites, translocation break points and transcriptionally active regions [3,13,14,15] which are preferred by the virus for its integration into the human genome. On integration within or near a gene, the virus can bring about a change in its expression which may eventually lead to alterations in cellular growth and proliferation. Also, viral integration can render both viral coding genes as well as the cellular genes susceptible to epigenetic changes which could regulate their expression. Hence, the integration of HPV into the human genome is considered an important event in cervical carcinogenesis.

The aim of this study was HPV genotyping and identification of site of integration of two HR-HPV types (16 and 18), along with evaluation of the prognostic value of integration site, in locally advanced cervical cancers in Indian women.

Materials and Methods
Clinical Samples
Pretreatment cervical tumor biopsies, predominantly from FIGO stage IIIB, were obtained from patients (median age, 50 years; age range, 33–80 years) undergoing radiotherapy alone or concomitant chemo-radiation at the Radiation Oncology Department, Tata Memorial Hospital, Mumbai, after obtaining IRB approval. A generic consent for basic research was obtained prior to obtaining the biopsies. However, for the current study a consent waiver was obtained from the Hospital Ethics Committee. The biopsies were obtained from histologically proven, primary
cervical tumor, before the start of radical radiation therapy and were coded for de-identification by the physician prior to testing. The samples were collected in liquid nitrogen and stored at 

\(-80\)°C until further use. All the samples were assigned a laboratory code to maintain confidentiality.

### Processing of tumor samples

Frozen tissues were cryocut for extraction of DNA and RNA. For DNA extraction, five 30 μm sections were collected in STE buffer (0.1 M NaCl, 0.05 M Tris pH 7.5, 1 mM EDTA, 1% SDS) containing 10 mg/ml Proteinase K (USB, Cleveland, OH, US). DNA was isolated by standard phenol-chloroform method. For isolation of total RNA, RNeasy Mini Kit (Qiagen, Hilden, Germany) was used. Ten 30 μm sections were collected in RLT buffer containing guanidine thiocyanate provided in the kit and processed following manufacturer’s instructions. DNAse treatment of the RNA samples was carried out using DNA free kit (Ambion, Austin, TX, US).

### HPV genotyping by high throughput luminex array

Genotyping of 24 HPV types which included 15 high-risk types (16, 18, 31, 33, 35, 39, 45, 51,52, 56, 58, 59, 68, 73, and 82), 3 putative high-risk types (26, 53, and 66), and 6 low-risk types (6, 11, 42, 43, 44, and 70) [1,2] was carried out using multiplex HPV genotyping array (Multimetrix GmbH, Heidelberg, Germany) based on luminex xMAP technology. As per the manufacturer’s instructions, PCR was carried out using sets of biotinylated broad range primers in a total volume of 50 μL containing 3.5 mM

---

**Figure 1. Flowchart depicting summary of the study.** Genotyping was carried out on 270 advanced stage cervical cancer samples by high-throughput, GP5*/6* primers based luminex array; consensus MY09/11 and SPF1/2 primers. HPV positivity was 95% (257/270). APOT assay was done on 86 HPV16* and/or HPV18* samples, with good clinical follow-up and good quality RNA. In 18 samples, only episomal form of HPV was identified, rest 68 hinted toward possible integration. Site of integration could be predicted with high score by BLAST and/or BLAT in 48 samples.

doi:10.1371/journal.pone.0041012.g001

[1] Ploner A, Dallapiccola B, Lebbe C, et al. (2008) HPV genotyping by high throughput luminex array. PLoS ONE 3(11): e3839. doi:10.1371/journal.pone.0003839

[2] Ploner A, Cetin S, Cellini MR, et al. (2009) Genotyping of 24 HPV types by high throughput luminex array. PLoS ONE 4(3): e4876. doi:10.1371/journal.pone.0004876
MgCl₂, 200 μM dNTPs, 0.75 unit of Taq DNA polymerase and 1 μl primer mix. The amplification steps included an initial DNA denaturation at 94°C for 5 min, followed by 40 cycles of denaturation for 20 s at 94°C, annealing for 30 s at 38°C, and extension for 1 min 20 s at 71°C, before a final extension for 4 min at 71°C. PCR positive samples were then subjected to the luminex run. Ten microlitres of the PCR product was mixed with the luminex bead mix containing distinct bead populations coupled to 24 HPV types. After thermal denaturation, the target sequences were hybridized to bead-bound probes. The hybridized PCR products were labeled by binding to R-phycoerythrin conjugated streptavidin. The read-out was obtained in the luminex bioanalyzer (Luminex Corporation, Austin, TX, USA). HPV types were discerned according to the unique bead signature, whereas the presence of PCR products was determined by phycoerythrin fluorescence. An analytical sensitivity cut-off was calculated based on the negative control which was deducted from each of the read-out.

HPV genotyping by PCR using MY09/11 and SPF1/2 primers

Since the amount of DNA available for the study was limiting, β-actin PCR was done only in those samples which failed to show amplification by GP5+/6+ primers (n = 92). These were further screened for HPV by PCR using MY09/11 L1 primers (Table S1) and SPF1/2 primers [16]. PCR was carried out in a reaction volume of 25 μl containing, 1.5 mM MgCl₂, 10μM of each primer, 200 μM dNTPs and 0.75 unit of Taq DNA polymerase. The samples which tested positive for HPV either by MY09/11 or SPF1/2 or both were further genotyped for the two most common HR-HPV types- HPV16 and 18 using HPV16/18 specific primers (Table S1). Since the amount of DNA was limiting, SPF 1/2 PCR could not be carried out in 4 of the 92 samples.

Association of HPV16, HPV18 and HPV16/18 infection with clinical outcome

The genotyping data for the two HR-HPV types, HPV16, HPV18 and HPV16/18 together, where adequate follow-up data was available was compared with the clinical outcome of the patients. Kaplan-Meier analysis (SPSS 15.0) was done to determine association between infection with these HR-HPV types and recurrence of disease. Disease free survival was considered from start of radiation therapy to the time when recurrence occurred or till last follow-up. Statistical significance was evaluated using the log-rank test (SPSS 15.0).

Identification of integration site by APOT assay

Samples (n = 86) positive for HPV16, HPV18 or both and with an adequate clinical follow-up (minimum 1yr or till occurrence of first event, whichever was earlier) were taken to study viral integration using Amplification of Papillomavirus Oncogene Transcripts (APOT) assay, as described by Klaes et al [6]. Briefly, total RNA (0.5–1 μg) was reverse transcribed using oligo(dT)17-primer coupled to a linker sequence ([dT]17–p3) [17] and 50 units
of Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA) for 1 h at 42°C. PCR with β-actin primers was carried out to check the integrity of the cDNA. First strand cDNA was amplified using HPV E7–specific primer (p1–16 specific for HPV16 and p1–18 specific for HPV18) as forward primers and linker p3 as the reverse primer (Table S1). The PCR amplification was carried out in a reaction volume of 50 μL containing 2.5 mM MgCl2, 200 μM dNTPs, 25 μM of each primer and 1 unit of Taq DNA polymerase. The reaction comprised of an initial denaturation step at 94°C for 2 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and extension at 72°C for 4 min. This was followed by a final extension at 72°C for 20 min. Next, 7 μL of the PCR product was used as template for nested PCR using forward primers p2–16 specific for HPV16 or p2–18 specific for HPV18 and (dT)17–p3 as reverse primer (Table S1). The PCR conditions were same as that of first PCR except that the annealing temperature was 66°C.

Cloning of fusion transcripts

Amplicons other than the major episomal transcripts (∼1050 bp for HPV16 and ∼1000 bp for HPV18) were suspected to be derived from the integrated HPV genomes. These were excised from the gel and DNA isolated using GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Buckinghamshire, UK). The isolated DNA was either sequenced directly or following cloning into pTZ57R/T vector using the InsTA PCR Cloning Kit (Fermentas, Lithuania, EU), on DNA sequencer (3100 Avant Genetic analyzer, Applied Biosystems, Foster City, CA, USA). The chromosomal integration loci were determined using National Centre for Biotechnology Information (BLAST) and the University of California, Santa Cruz (UCSC) hg19 (Feb. 2009) (BLAT) human genome assemblies. Further, the integration sites were checked for the presence of fragile sites and any genes of known identity by using NCBI fragile site map viewer and the UCSC Blat tool respectively.

Association of viral integration with clinical outcome

The data obtained was compared with the clinical outcome of the patients. Kaplan-Meier analysis (SPSS 15.0) was done to determine the association of the viral state (episomal/integrated) with recurrence of the disease. Disease free survival was considered from start of radiation therapy to the time when recurrence occurred or till last follow-up (median follow-up for 86 cases was 44 months). Statistical significance was evaluated using the log-rank test (SPSS 15.0).

Results

HPV genotyping by high throughput luminex array

Although there are a few reports on different high risk HPVs in Indian women, here we report 15 high risk HPVs, 3 intermediate risk and 6 low risk HPV types using the high throughput luminex array. The primers provided in the luminex array kit for HPV genotyping were biotinylated, broad range GP5+/GP6+ primers. Using this primer set for PCR, we obtained 178 out of 270 samples positive for HPV (Figure 1). The HPV positive samples were further subjected to hybridization to bead-bound probes by luminex array as described earlier. One hundred sixty nine samples were found to hybridize to the different HPV probes whereas 9 samples were negative. These 9 samples could have HPV infection not included in the 24 types detected by the kit. Out of 169 HPV positive samples, 168 samples were positive for one or more HR-HPV types indicating a high association of cervical cancer with HR-HPV infection. Among these, HPV16 and/or HPV18 infection were most common – 114 samples being positive for HPV16 alone, 6 samples for HPV18 alone and 16 samples for both HPV16 and HPV18 (Figure 2).

HPV genotyping by PCR using MY09/11 and SPF1/2 primers

In order to estimate the true HPV positivity in the 270 cases, the 92 cervical cancer biopsies negative for HPV by luminex array, were first subjected to PCR using β-actin primers to check the quality of DNA. All were found to be positive for β-actin. Next they were subjected to PCR using MY09/11 and SPF1/2 primers. Twenty five out of 92 samples were found to be positive for HPV by MY09/11 PCR. Since the amount of DNA was limiting, SPF 1/2 PCR could not be carried out in 4 of the 92 samples. Screening with SPF1/2 primers revealed 79 samples to be HPV positive. These 79 samples also included the 25 samples that tested HPV positive by MY09/11 PCR. The HPV positivity was therefore calculated taking into account the results from luminex...
| Sample ID | Histology | HPV type | Integration locus | Gene | Fragile site involved |
|-----------|-----------|----------|-------------------|------|----------------------|
| CT 712    | SCC       | 16       | 1p36.12           | ALPQTL2 | FRA1A(1p36) com     |
| CT 700    | SCC       | 16       | 1p36.23           | -     | FRA1A(1p36) com     |
| CT 702    | SCC       | 16       | 1p36.23           | -     | FRA1A(1p36) com     |
| CT 709    | SCC       | 16       | 1p36.33           | -     | FRA1A(1p36) com     |
| CT 1138   | SCC       | 16       | 3q28              | FRA3C(3q27) | Flanked by FRA8E(8q24.1) rare; FRA8C(8q24.1) com; FRA8D(8q24.3) com |
| CT 755    | SCC       | 16       | 3q23              | SLC25A36 | -                    |
| CT 866    | SCC       | 16       | 3q23              | SLC25A36 | -                    |
| CT 864    | SCC       | 16       | 3q23              | -     | FRA1A(1p36) com     |
| CT 1210   | SCC       | 16       | 3q26.2            | MECOM | -                    |
| CT 723    | SCC       | 16       | 3q26.33           | SOX2  | FRA3C(3q27) com     |
| CT 706    | SCC       | 16       | 3q26.33           | -     | FRA3C(3q27) com     |
| CT 711    | SCC       | 16       | 3q27              | LEPREL1 | FRA3C(3q27) com     |
| CT 739    | SCC       | 16       | 3q28              | TP63  | FRA3C(3q27) com     |
| CT 999    | SCC       | 16       | 4q13.3            | IL8(-3kb) | -                    |
| CT 1114   | SCC       | 16       | 4q21.22           | HNRPDL | -                    |
| CT 893    | SCC       | 16       | 6q22.31           | -     | -                    |
| CT 1117   | AC        | 16       | 6q22.31           | -     | -                    |
| CT 1122   | SCC       | 16       | 6q23.3            | PDE7B  | -                    |
| CT 1019   | SCC       | 16       | 7q11.21           | TYW1  | FRA7J(7q11) com     |
| CT 796    | SCC       | 16       | 8p11.21           | -     | -                    |
| CT 915    | SCC       | 16       | 8p11.21           | -     | -                    |
| CT 1160   | SCC       | 16       | 8q24.21           | MYC/PVT | Flanked by FRA8E(8q24.1) rare; FRA8C(8q24.1) com; FRA8D(8q24.3) com |
| CT 714    | SCC       | 16       | 9q22.32           | C9orf3 | FRA9D(9q22.1) com   |
| CT 1162   | SCC       | 16       | 9q22.32 and Episomal | C9orf3 | FRA9D(9q22.1) com   |
| CT 753    | SCC       | 18       | 9q34.11           | SLC25A25 | -                    |
| CT 821    | SCC       | 18       | 10q23.33          | -     | FRA10A(10q23.3) rare |
| CT 859    | SCC       | 16       | 10q23.31          | PTEN  | FRA10A(10q23.3) rare |
| CT 1169   | SCC       | 16       | 11q13.1 and Episomal | DRAP1 | FRA11H(11q13) com   |
| CT 1183   | SCC       | 16       | 11q13.1           | DRAP1  | FRA11H(11q13) com   |
| CT 836    | SCC       | 16       | 11q14.3           | -     | FRA11F(11q14.2) com |
| CT 871    | AC        | 18       | 11q23.3           | ARCNI  | FRA11G(11q23.3) com |
| CT 1094   | SCC       | 16       | 13q               | -     | -                    |
| CT 927    | SCC       | 16       | 13q21.3           | POMP  | -                    |
| CT 896    | SCC       | 16       | 13q22.1           | -     | Flanked by FRA13B(13q21) com |
| CT 976    | SCC       | 16       | 13q22.1           | KLF5  | Flanked by FRA13B(13q21) com |
| CT 848    | SCC       | 16       | 17q12 and Episomal | HNF1B | -                    |
| CT 914    | SCC       | 16       | 17q23.1           | VMP1  | FRA17B(17q23.1) com |
array and SPF1/2 PCR. The overall HPV positivity in this cohort was found to be 95% (257/270). Further genotyping of the 79 samples, using HPV 16/18 specific primers, showed 49 samples to be positive for HPV16. None of these 79 samples were positive for HPV18. Therefore, the prevalence of HPV16 and/or HPV18 in this cohort was 69% (185/270) (Figure 1).

**Association of HPV16, 18 and dual infection with clinical outcome**

Kaplan-Meier survival analysis data for 125 patients with HPV type16, 18 and dual infection and with adequate clinical follow-up (median follow-up for 125 cases was 54 months), revealed that there was no significant difference between infection with these two HR-HPV types in terms of disease outcome (Figure S1).

**Physical state of virus and clinical outcome**

Out of 125 HPV16, HPV18 or dual HPV positive samples, a sub-set of 86 samples with good quality RNA, were taken to study the physical state and/or site of viral integration by APOT assay. In most of the cases, the viral genome was found to be integrated (n = 68), whereas in 21% (n = 18) only episomal transcripts could be identified. In 12 cases with integrated viral genome, episomal form of HPV was also detected (Figure 1). The physical state of the virus (episomal/ integrated) was associated with the disease outcome. Survival data revealed that 16 out of 18 patients with only episomal form of HPV (16 and/or 18), had disease free survival as compared to those with integrated form of the virus, indicating a good clinical outcome (p = 0.067, representing a borderline significance) (Figure 3). The clinical outcome of all the patients where the viral integration was studied is shown in Table S2.

**Identification of viral integration site**

In order to understand whether the integration event is random or there is some preference for certain sites within the chromosomes, the sequencing data for 68 cases derived from APOT assay were investigated by Blast and/or Blat. The site of integration could be predicted with a high score in 48 cases (Table S3a), for the remaining 20 cases the score was low (Table S3b). Only those cases where the integration site was predicted with high score (n = 48) were analyzed further for different features associated with the same. The sites of integration were found to be distributed throughout the genome. However,

| Sample ID | Histology | HPV type | Integration locus | Gene | Fragile site involved |
|-----------|-----------|----------|------------------|------|----------------------|
| CT 1097   | SCC       | 16       | 18q11.2          | -    | -                    |
| CT 740    | SCC       | 18       | 18q21.3          | -    | FRA18B(18q21.3) com  |
| CT 906    | SCC       | 16       | Episomal         | -    | -                    |
| CT 889    | SCC       | 16       | 19q13.43 and Episomal | - | FRA19A(19q13) com |
| CT 918    | SCC       | 16       | 20q11.21 and episomal | COX4I2 | - |

| Sample ID | Histology | HPV type | Integration locus | Gene | Fragile site involved |
|-----------|-----------|----------|------------------|------|----------------------|
| CT 1170   | SCC       | 16       | 20q11.21         | COX4I2 | - |
| CT 839    | SCC       | 16       | 20q13.13         | -    | -                    |
| CT 1015   | SCC       | 16       | -                | -    | -                    |
| CT 1082   | SCC       | 16       | -                | -    | -                    |
| CT 1101   | SCC       | 16       | -                | -    | -                    |
| CT 1107   | SCC       | 16       | -                | -    | -                    |
| CT 1108   | SCC       | 16       | -                | -    | -                    |
| CT 1135   | SCC       | 16       | -                | -    | -                    |
| CT 1161   | SCC       | 16       | -                | -    | -                    |
| CT 759    | SCC       | 16       | -                | -    | -                    |
| CT 787    | SCC       | 16       | -                | -    | -                    |
| CT 792    | SCC       | 16       | -                | -    | -                    |
| CT 800    | SCC       | 16       | -                | -    | -                    |
| CT 828    | SCC       | 16       | -                | -    | -                    |
| CT 868    | SCC       | 16       | -                | -    | -                    |
| CT 887    | SCC       | 16       | -                | -    | -                    |
| CT 905    | SCC       | 18       | -                | -    | -                    |
| CT 934    | SCC       | 16       | -                | -    | -                    |
| CT 935    | SCC       | 16       | -                | -    | -                    |
| CT 951    | SCC       | 16       | -                | -    | -                    |

Key: – SCC: Squamous cell carcinoma, AC: Adenocarcinoma, Com: Common Fragile site

**Table 1. Cont.**

| Sample ID | Histology | HPV type | Integration locus | Gene | Fragile site involved |
|-----------|-----------|----------|------------------|------|----------------------|
| CT 1097   | SCC       | 16       | 18q11.2          | -    | -                    |
| CT 740    | SCC       | 18       | 18q21.3          | -    | FRA18B(18q21.3) com  |
| CT 906    | SCC       | 16       | Episomal         | -    | -                    |
| CT 889    | SCC       | 16       | 19q13.43 and Episomal | - | FRA19A(19q13) com |
| CT 918    | SCC       | 16       | 20q11.21 and episomal | COX4I2 | - |

| Sample ID | Histology | HPV type | Integration locus | Gene | Fragile site involved |
|-----------|-----------|----------|------------------|------|----------------------|
| CT 1170   | SCC       | 16       | 20q11.21         | COX4I2 | - |
| CT 839    | SCC       | 16       | 20q13.13         | -    | -                    |
| CT 1015   | SCC       | 16       | -                | -    | -                    |
| CT 1082   | SCC       | 16       | -                | -    | -                    |
| CT 1101   | SCC       | 16       | -                | -    | -                    |
| CT 1107   | SCC       | 16       | -                | -    | -                    |
| CT 1108   | SCC       | 16       | -                | -    | -                    |
| CT 1135   | SCC       | 16       | -                | -    | -                    |
| CT 1161   | SCC       | 16       | -                | -    | -                    |
| CT 759    | SCC       | 16       | -                | -    | -                    |
| CT 787    | SCC       | 16       | -                | -    | -                    |
| CT 792    | SCC       | 16       | -                | -    | -                    |
| CT 800    | SCC       | 16       | -                | -    | -                    |
| CT 828    | SCC       | 16       | -                | -    | -                    |
| CT 868    | SCC       | 16       | -                | -    | -                    |
| CT 887    | SCC       | 16       | -                | -    | -                    |
| CT 905    | SCC       | 18       | -                | -    | -                    |
| CT 934    | SCC       | 16       | -                | -    | -                    |
| CT 935    | SCC       | 16       | -                | -    | -                    |
| CT 951    | SCC       | 16       | -                | -    | -                    |

**Table 1.**

| Sample ID | Histology | HPV type | Integration locus | Gene | Fragile site involved |
|-----------|-----------|----------|------------------|------|----------------------|
| CT 1097   | SCC       | 16       | 18q11.2          | -    | -                    |
| CT 740    | SCC       | 18       | 18q21.3          | -    | FRA18B(18q21.3) com  |
| CT 906    | SCC       | 16       | Episomal         | -    | -                    |
| CT 889    | SCC       | 16       | 19q13.43 and Episomal | - | FRA19A(19q13) com |
| CT 918    | SCC       | 16       | 20q11.21 and episomal | COX4I2 | - |

Key: – SCC: Squamous cell carcinoma, AC: Adenocarcinoma, Com: Common Fragile site

doi:10.1371/journal.pone.0041012.t001
integration was more frequent at the chromosomal loci 1p (n = 7), 3q (n = 0), 13q (n = 4), 6q (n = 4), 11q (n = 4) and 20q (n = 4) (Figure 4). Only one sample showed HPV integration at two chromosomal loci simultaneously. Some of the recurrent integration sites were also checked at the genomic level by carrying out genomic DNA PCR with HPV E7 primers as the forward primer and primers specific to a given chromosomal region as the reverse one (Figure S2).

Features associated with HPV integration

Using NCBI Fragile site Map Viewer it was observed that 60% of integrations (29/48) were located in or close to a common or rare fragile site. The rest of the integration sites were not associated with any fragile sites (Table 1). Using the UCSC Blat tool 50% of the sequences (28/48) were observed to be either within or nearby protein coding genes. These genes belonged to various categories ranging from oncogenes, transcription factors, and tumor suppressor genes (Table 1).

Discussion

It is proven beyond doubt that infection by HPV plays a major role in the etiology of cervical cancer. Reports from different parts of the sub-continent indicate a prevalence of HPV ranging from 75–99% [18–30]. In the present study we report 95% HPV positivity using three different primer sets. It is apparent from this study that a single set of primers is not sufficient to estimate the true HPV infectivity. Of the various HPV genotypes HPV16 was most common (60%), followed by infection with HPV18 alone (2%). Dual infection with HPV16/18 (6%) and HPV16/45 (3%) was also observed. These results are in concordance with other studies from the Indian subcontinent which reports 57–65% HPV16 positivity, followed by HPV18, 45, and 33 in cervical neoplasia [19,20,29].

Integration of the virus is common in late stage cervical cancers and is considered an important event in the progression of the disease. Integration generally occurs downstream of the early genes E6 and E7, often in the E1 or E2 region. The E2 gene is transcriptionally inactivated once the virus gets integrated due to disruption of its open reading frame. Viral E2 gene has been extensively studied and is known to play a role in viral replication as well as negative regulation of E6 and E7 genes [31].

Various techniques have been used to study integration of the virus, such as Ligation-mediated PCR [32], Restriction site-PCR [15] and APOT assay [6]. In order to limit our study to integration sites with transcriptionally active viral genome, APOT assay was chosen. Also, APOT assay allows detection of integrated viral genome in clinical lesions even in the presence of a large excess of nonintegrated episomal form of viral genomes [6,33].

The frequency of viral integration into the host genome in cervical carcinomas has been reported to be as high as 100% in HPV18+ tumors [34] and up to 80% in HPV16+ tumors [35]. In our study we found four HPV18+ samples where the virus was integrated and one HPV18+ sample where the virus was episomal. The incidence of integration in HPV16+ samples was higher. The mechanism of HR-HPV integration is not fully understood. It is speculated that integration might represent a chance occurrence, the probability of which increases with the frequency of double-strand breaks (DSBs) in host and viral DNA. Chromosomal fragile sites could represent the hotspots for HR-HPV integration.

The physical state and/or site of integration was studied in 86 cervical tumour samples infected with either or both of two HR-HPVs, HPV16 and HPV18, and with an adequate clinical follow-up. Episomal form of HPV was observed in 18 cases. Presence of only episomal form in these patients with advanced disease stage (predominantly FIGO stage IIIb), could indicate that either HPV integration is not solely responsible for the progression of the disease; or it could be a limitation of the technique resulting in failure of amplification of the integrant derived transcript. Recent studies have confirmed presence of only episomal form of the virus in advanced cervical squamous cell carcinomas [33,36]. In addition, since APOT works on the basis of annealing of the Frohman primer to the polyA tail, cases in which polyA tail is located at a great distance from the forward primer, might not be amenable to amplification by PCR.

In the present study, we observed 12 samples where both integrated as well as episomal forms of the virus were present. In such cases, E2 may be available in trans to modulate the expression levels of oncogenic E6 and E7 [37]. Also according to the report by Pett et al., loss of episomes is as much important as integration of the virus into the host genome for progression of lesions to cervical neoplasia [38]. It would be interesting to see the expression of E2 and E6/E7 in cases where HR-HPV is present in episomal as well as integrated form or in samples where HPV is only episomal.

There are reports that HR-HPV proteins other than E6/E7 induce chromosomal instability and transformation [39]. It is reported that E2 stabilizes Skp2, an oncogene and this could lead to activation of S-phase entry [39]. Hamid et al., [40] have also suggested a role for E2 in cell proliferation. Since cells in S-phase are more responsive to radiation, cancers with episomal E2 could be more responsive to radiation treatment. Comparison of the physical state of the virus (episomal/integrated) with the clinical outcome after radical radiotherapy revealed that patients with episomal form of the virus had increased disease free survival compared to those with integrated form. This observation is supported by various reports which state that the integration event is associated with a decreased disease free survival [41,42]. However, there are contrasting reports as well, according to which physical state of the virus does not correlate with disease free survival [43,44]. This needs to be studied further.

Although integration sites were distributed throughout the genome in different samples, there was a preference for certain chromosomal loci such as 1p, 3q, 6q, 11q, 13q, 6q and 20q. Certain specific regions in some of these loci such as 1p36.23, 1p36.33, 3q26, 3q28 and 20ql1.21 showed repeated integrations, indicating that integration might not be a random event. Reports from studies involving western populations indicate that integration of the virus occurs most commonly at 8q chromosomal locus [3,45,46]. Integration at the 8q locus in our study was observed in only 1 out of 48 cases. This may be due to the difference in the ethnicity of the two populations.

The 3q, 13q and 20q loci besides being preferential target for HPV integration have been reported to be sites for genomic instability associated with cervical cancer. Gain of 3q and 20q, while loss of 13q has been reported in various stages of the disease [47–49]. Also more recent reports show that a significant association exists between genomic rearrangement and HPV integration [46]. It would therefore be interesting to study whether the preferential integration of the virus into these loci has a role to play in inducing genomic instability.

Most of the integrations (28/48) were found to be located within or near certain genes. This could indicate that the virus prefers transcriptionally active regions for the integration event. Such genes included oncogenes such as myc, transcription factors like TP63, MECOM, etc. This observation is supported by previous report by Wentzensen et al wherein they have shown involvement of tumour related genes (myc and TP63) in HPV integration.
process [50]. Studies in our lab have shown that some of the genes within which integration was observed, such as ABCB10, SLC25A36, IL8, COX4I2, HNF1B, myc, demonstrated increased expression (unpublished data), thereby indicating that upon integration within or near a particular gene the virus may bring about changes in gene expression.

Integration of the virus near or within fragile sites has frequently been reported [15,45,50–52]. Fragile sites are specific regions in the chromosomes that nonrandomly undergoes break in response to certain stress. This makes genes in or near these sites susceptible to foreign DNA integration. In our study 29/48 integrations were located within or near a common or rare fragile site which is in concordance with previous reports. Another observation of our study was that patients with viral integration at chromosomal loci 3q, 13q and 20q showed the worst prognosis amongst all. Whether this can have any clinical implication in prognosis of cervical cancer would be interesting and challenging to study.

Supporting Information

Figure S1 Kaplan-Meier analysis for two HR-HPV types – HPV16 and/or HPV18 and disease outcome. Kaplan-Meier survival analysis for HPV16 and/or HPV18 in 125 patients who had a good clinical follow up was carried out. Patients with HPV16 infection alone showed a trend towards better disease free survival as compared to HPV18 infection alone and dual infection with HPV16/18.

Figure S2 Genomic DNA PCR of the recurrent integration sites. Representative gel images (a, b) showing HPV integration at the genomic level. Recurrent integrations at chromosomal loci 1p36.23, 3q28, 6q23.3, 8p11.21 and 11q13.1 is depicted.

(TIF)

Table S1 Primer sequences.

(DOCX)

Table S2 Clinicopathological data for all cases where the viral integration was studied.

(DOCX)

Table S3 Sequence of HPV integration sites in the genome in 68 cases. a) Integration sites for 48 cases with a high prediction score, b) Integration sites for 20 cases with a low prediction score.

(DOCX)

Acknowledgments

The authors wish to acknowledge late Dr. K.A. Dinshaw and all individuals from the Gynaecology Disease Management Group, Tata Memorial Hospital, who were involved in judiciously compiling the clinical history and collecting and storing the biopsies from cervical cancer patients. Help from Ms. Sadhana Kannan (ACTREC) in statistical analysis and Ms. Tabish Hussain (ACTREC) for her valuable inputs in preparing the manuscript are gratefully acknowledged.

Author Contributions

Conceived and designed the experiments: RM PD. Performed the experiments: PD AT. Analyzed the data: PD. Contributed reagents/materials/analysis tools: RM. Wrote the paper: PD RM. Sample collection, patient follow-up, clinical inputs: UM SKS. Pathological examination of biopsies: KD.

References

1. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, et al. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518–527.
2. Schmitt M, Bravo IG, Snijders PJJ, Gissmann L, Pawlita M, et al. (2006) Head-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504–512.
3. Wentzensen N, Vinsavourov S, von Knebel Doeberitz M (2004) Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64: 3878–3884.
4. Rechtold V, Beard P, Raj K (1992) Human papillomavirus type 16 E2 protein has no effect on transcription from episomal viral DNA. J Virol 77: 2021–2028.
5. Romanczuk H, Howley PM (1992) Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci U S A 89: 3159–3163.
6. Klaes R, Woerner SM, Rädder R, Wentzensen N, Duerst M, et al. (1999) Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncosequences. Cancer Res 59: 6132–6136.
7. Couturier J, Sasure-Garau X, Schneider-Maunoury S, Labih A, Orth G (1991) Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J Virol 65: 4354–4359.
8. Choo KB, Pan CG, Han SH (1987) Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161: 259–261.
9. Di Luca D, Pieri M, Sofasan B, Rotola A, Monini P, et al. (1986) Human papillomavirus type 16 DNA in genital tumours: a pathological and molecular analysis. J Gen Virol 67 (Pt 3): 583–589.
10. Jeon S, Allen-Hoffmann BL, Lambert PF (1995) Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 69: 2989–2997.
11. Jeon S, Lambert PF (1995) Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A 92: 1654–1658.
12. Yu T, Ferber MJ, Cheung TH, Chung TK, Wong YF, et al. (2005) The role of viral integration in the development of cervical cancer. Cancer Genet Cytogenet 158: 27–34.
13. Zieger C, Wentzensen N, Vinsavourov S, Kiselev F, Einert K, et al. (2003) A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 22: 3977–3984.
14. Koopman LA, Sanhai K, van Eendenburg JD, Bezrookove V, Kenter GG, et al. (1999) Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. Cancer Res 59: 5615–5624.
15. Thorland EC, Myers SL, Persing DH, Sarkar G, McGovern RM, et al. (2000) Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites. Cancer Res 60: 5916–5921.
16. Klet E, van Doorn LJ, ter Schegget J, Schrauwen L, van Krimpen K, et al. (1998) Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 153: 1731–1739.
17. Frohman MA, Dush MK, Martin GR (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A 85: 8998–9002.
18. Banti P, Chandha P, Bamezai RN, Siddhip M, Saranath D, et al. (2011) MassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer. J Clin Microbiol 49: 3537–3544.
19. Banti P, Roychowdhury S, Bahia UD, Chauhdury S, Kothari S, et al. (2009) Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-center study. Asian Pac J Cancer Prev 10: 27–34.
20. Bhatla N, Lal N, Bao YP, Ng T, Qiao YL (2008) A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine 26: 2811–2817.
21. Chatterjee R, Mandal B, Bandyopadhyay S (2005) Detection of HPV DNA in cervical carcinomas by PCR and hybrid capture assay. Indian J Pathol Microbiol 46: 596–599.
22. Franceschi S, Rajkumar T, Vaccarella S, Gajalakshmi V, Sharmila A, et al. (2013) Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer 107: 127–133.
23. Pericakay A, Abraham P, Sathish N, John S, Shah K, et al. (2006) Human papillomavirus genotypes associated with cervical neoplasia in India. Int J Gynecol Cancer 16: 1291–1295.
24. Pillai RM, Babu JM, Jissa VT, Lakshmi S, Chiplunkar SV, et al. (2010) Region-wise distribution of high-risk human papillomavirus types in squamous cell carcinomas of the cervix in India. Int J Gynecol Cancer 20: 1046–1051.
25. Saranath D, Khan Z, Tandle AT, Dedhia P, Sharma B, et al. (2002) HPV16/18 prevalence in cervical lesions/cancers and p53 genotypes in cervical cancer patients from India. Gynecol Oncol 86: 157–162.

26. Travassos CM, Anand M, Samarth M, Deshpande A, Kannan-Sinha C (2008) Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India. J Biosci 33: 73–80.

27. Singh A, Datta P, Jain SK, Bhatia N, Dutta Gupta S, et al. (2009) Human papillomavirus genotyping, variants and viral load in tumors, squamous intraepithelial lesions, and controls in a North Indian population subset. Int J Gynecol Cancer 19: 1642–1648.

28. Doodhkar K, Gheit T, Vacciarella S, Romao CC, Tenet V, et al. (2012) Prevalence of human papillomavirus types in cervical lesions from women in rural Western India. J Med Virol 84: 1054–1060.

29. Grace Nirmala J, Narendhirakannan. (2012) RT Detection and genotyping of HPV-18 DNA in cervical carcinoma. Mol Pathol 52: 275–282.

30. Sowjanya AP, Jain M, Poli UR, Padma S, Das M, et al. (2005) Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis 5: 116.

31. Xue Y, Bellanger S, Zhang W, Lim D, Low J, et al. (2010) HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. Cancer Res 70: 5316–5325.

32. Liif F, Klæs R, Nees M, Durst M, Hellmann V, et al. (2001) Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer. Int J Cancer 92: 9–17.

33. Vinokurova S, Wentzensen N, Kraus I, Klæs R, Driesch C, et al. (2008) Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68: 307–313.

34. Corden SA, Sant-Cassia LJ, Easton AJ, Morris AG (1999) The integration of HPV-18 DNA in cervical carcinoma. Mol Pathol 52: 275–282.

35. Mehlheimer P, Vinokurova S, Wentzensen N, Bärtser G, von Knebel Doeberitz M (2004) DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res 10: 3059–3065.

36. Gray E, Pett MR, Ward D, Winder DM, Stanley MA, et al. (2010) In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res 70: 4081–4095.

37. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM (2006) Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 44: 1755–1762.

38. Pett MB, Heideman MT, Palmer RD, Yeo GS, Shiyi MK, et al. (2006) Selection of cervical keratinocytes containing integrated HPV16 associates with epissome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A 103: 3822–3827.

39. Bellanger S, Tan CL, Wei H, He PP, Thierry F (2009) The human papillomavirus type 18 E2 protein is a cell cycle-dependent target of the SCFSkp2 ubiquitin ligase. J Virol 84: 437–444.

40. Hamid NA, Brown C, Gaston K (2009) The regulation of cell proliferation by the papillomavirus early proteins. Cell Mol Life Sci 66: 1700–1717.

41. Kalantari M, Karshen F, Kristensen G, Holm R, Høgmar B, et al. (1998) Disruption of the E1 and E2 reading frames of HPV-16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 17: 146–153.

42. Vernon SD, Unger ER, Miller DL, Lee DR, Reeves WC (1997) Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int J Cancer 74: 50–56.

43. Holm R, Kraus I, Skomedal H, Langerød A, Kristensen GB, et al. (2008) Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma. Open Virol J 2: 74–81.

44. Nanambu L, Meenakumari B, Swaminathan R, Rajkumar T (2009) Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev 10: 353–360.

45. Kraus I, Driesch C, Vinokurova S, Hovig E, Schneider A, et al. (2008) The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res 68: 2514–2522.

46. Peter M, Stransky N, Couturier J, Hupe P, Barillot E, et al. (2010) Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol 221: 320–330.

47. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, et al. (2004) Chromosomal amplifications, 3q gain and deletions of 2q33–q37 are the frequent genetic changes in cervical carcinoma. Genes Chromosomes Cancer 47: 755–765.

48. Scotto I, Narayana G, Nandula SV, Arias-Pulido H, Subramaniam S, et al. (2008) Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47: 590–595.

49. Wilting SM, de Wilde J, Meijer CJ, Berkhof J, Yi Y, et al. (2008) Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer 47: 735–755.

50. Wentzensen N, Riddler R, Klæs R, Vinokurova S, Schaarber U, et al. (2002) Chromosomal amplifications, 3q gain and deletions of 2q33–q37 are the frequent genetic changes in cervical carcinoma. Int J Gynecol Pathol 17: 146–153.

51. Matovina M, Sabol I, Grubisic G, Gasperov NM, Grce M (2009) Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47: 590–595.

52. Dall KL, Scarpini CG, Roberts I, Winder DM, Stanley MA, et al. (2012) HPV and Cervical Cancers in Indian Women.